S. Tolaney

H. Rugo, S. Tolaney, L. Damon, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Estimating long-term mortality in women with hormone receptor-positive breast cancer: The 'ESTIMATE' tool.

N. Lin, M. Hassett, S. Tolaney, 2022, European journal of cancer.

Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?

G. Curigliano, K. Punie, R. Barroso-Sousa, 2022, Cancer treatment reviews.

A phase Ib study of abemaciclib in combination with pembrolizumab for patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer (MBC) (NCT02779751): Interim results.

H. Rugo, P. Kabos, S. Tolaney, 2020 .

A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2- metastatic breast cancer (MBC).

C. Anders, P. Kabos, A. Awada, 2019, Journal of Clinical Oncology.

Abstract GS1-05: TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT)

E. Winer, L. Trippa, R. Bose, 2020 .

Incidence, characteristics, and management of central nervous system metastases in patients with inflammatory breast cancer

J. Bellon, N. Lin, M. Regan, 2022, Cancer.

A phase II study of tivantinib (ARQ-197) for metastatic triple-negative breast cancer.

E. Winer, C. Paweletz, P. Jänne, 2014 .

Overcoming Resistance to HER2-Directed Therapies in Breast Cancer

S. Tolaney, P. Tarantino, I. Schlam, 2022, Cancers.

Assessment of concentrations of abemaciclib and its major active metabolites in plasma, CSF, and brain tumor tissue in patients with brain metastases secondary to hormone receptor positive (HR+) breast cancer.

S. Tolaney, P. Kulanthaivel, P. K. Turner, 2016 .

Abstract PD05-01: CALGB 40302: Fulvestrant with or without Lapatinib as Therapy for Hormone Receptor Positive Advanced Breast Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Study

E. Winer, D. Lake, W. Barry, 2010 .

Benefit-risk trade-offs in treatment choice in advanced HER2 negative breast cancer: patient and oncologist perspectives.

S. Tolaney, K. Beusterien, K. McLaurin, 2022, Future oncology.

Abemaciclib for pre/perimenopausal women with HR+, HER2- advanced breast cancer.

P. Neven, G. Sledge, H. Rugo, 2018 .

E. Winer, Minetta C. Liu, R. Bose, 2021, Breast Cancer Research and Treatment.

Abemaciclib for the treatment of HR+/HER2- breast cancer

S. Tolaney, P. Exman, 2018 .

Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC)

E. Winer, L. Carey, W. Barry, 2013 .

Immunotherapy for early triple negative breast cancer: research agenda for the next decade

H. Rugo, F. André, G. Curigliano, 2022, NPJ breast cancer.

Emerging Targeted Therapies for Early Breast Cancer

S. Tolaney, E. Mayer, P. Tarantino, 2022, Drugs.

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

D. Berry, C. Perou, E. Winer, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract P5-19-13: Clinical activity of abemaciclib, an oral cell cycle inhibitor, in metastatic breast cancer

P. Wen, K. Flaherty, A. Tolcher, 2015 .

Abstract CT232: Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer

P. Wen, K. Flaherty, A. Tolcher, 2014 .

Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer.

P. Wen, K. Flaherty, A. Tolcher, 2014 .

M. Piccart, L. Carey, A. Bardia, 2022, European journal of cancer.

Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche

Shannon E. McCarthy, M. Hemberg, D. Dillon, 2021, Cell.

Abstract S4-05: Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Allianc

D. Berry, C. Perou, E. Winer, 2015 .

Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study

H. Rugo, H. Wildiers, L. Paz-Ares, 2022, npj Breast Cancer.

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer

E. V. Van Allen, B. Overmoyer, E. Mittendorf, 2022, Journal for ImmunoTherapy of Cancer.

Role of Immunotherapy in Early- and Late-Stage Triple-Negative Breast Cancer.

S. Tolaney, S. Morganti, 2023, Hematology/oncology clinics of North America.

Fluorouracil and dose-dense adjuvant chemotherapy in breast cancer: lessons learned from the 20-year-old GIM2 trial.

S. Tolaney, S. Morganti, 2022, The Lancet. Oncology.

Artificial intelligence in cancer research and precision medicine: Applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care.

L. Celi, C. Criscitiello, G. Curigliano, 2022, Cancer treatment reviews.

Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice

E. Winer, R. Gelman, H. Burstein, 2013, Breast Cancer Research and Treatment.

Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)

V. Valero, A. Wolff, H. Burstein, 2022, npj Breast Cancer.

Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer

G. Freeman, E. V. Van Allen, K. Polyak, 2022, Cancer immunology research.

Abstract CT325: Combination of the PARP inhibitor veliparib (ABT888) with irinotecan in patients with triple negative breast cancer: Preliminary activity and signature of response

J. Carpten, D. Craig, A. Chen, 2015 .

Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer

E. Winer, L. Trippa, N. Lin, 2021, The oncologist.

Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

Andres Forero, James N. Ingle, Vered Stearns, 2013, Clinical Cancer Research.

Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer

E. Winer, C. Paweletz, E. V. Van Allen, 2015, Investigational New Drugs.

Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer

N. Choudhry, S. Tolaney, M. Najafzadeh, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer

J. Califano, W. Westra, M. Zeiger, 2006, International journal of cancer.

Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors

E. Winer, F. Marty, S. Tolaney, 2015, Breast Cancer Research and Treatment.

Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

D. Berry, E. Mardis, C. Fan, 2018, Clinical Cancer Research.

Optimal treatment of early stage HER2‐positive breast cancer

R. Barroso-Sousa, S. Tolaney, S. Pernas, 2018, Cancer.

Role of Immunotherapy in Triple-Negative Breast Cancer.

S. Tolaney, T. Keenan, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

HER2-Low Breast Cancer: Pathological and Clinical Landscape.

F. Cardoso, F. Penault-Llorca, F. André, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.

E. Winer, W. Barry, D. Dillon, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance

S. Tolaney, S. Pernas, 2019, Therapeutic advances in medical oncology.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer

H. Rugo, S. Adams, A. Cimino-Mathews, 2021, Journal for ImmunoTherapy of Cancer.

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study

E. Elgabry, L. Molinero, R. Nanda, 2019, JAMA oncology.

TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial.

A. Tan, C. Anders, M. Mita, 2018 .

Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab.

H. Rugo, L. Gianni, P. Kabos, 2018 .

Abstract P1-09-01: A phase 1b study of abemaciclib plus pembrolizumab for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC)

P. Kabos, I. Smith, S. Tolaney, 2018 .

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

C. Hudis, J. Baselga, H. Rugo, 2017, Clinical Cancer Research.

Abstract PD6-13: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer

V. Karantza, M. Olivo, P. Kaufman, 2017 .

Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer

V. Karantza, S. Tolaney, G. Aktan, 2017 .

The Immunology of Hormone Receptor Positive Breast Cancer

E. Mittendorf, J. Agudo, R. Pastorello, 2021, Frontiers in Immunology.

CDK4/6 inhibition in breast cancer: current practice and future directions

E. Winer, S. Goel, S. Tolaney, 2018, Therapeutic advances in medical oncology.

Cancer Therapy : Preclinical Preclinical Activity Pro fi le and Therapeutic Ef fi cacy of the HSP 90 Inhibitor Ganetespib in Triple-Negative Breast Cancer

G. Shapiro, D. Proia, N. Spector, 2013 .

Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer

E. Winer, K. Polyak, R. Gelman, 2018, npj Breast Cancer.

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.

Tuan S. Nguyen, P. Wen, K. Flaherty, 2016, Cancer discovery.

Optimizing the Management of Metastatic HER2-Positive Breast Cancer

S. Goel, S. Tolaney, 2015, Current Breast Cancer Reports.

Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer

A. Tutt, R. Plummer, G. Shapiro, 2022, NPJ breast cancer.

Neoadjuvant and Adjuvant Chemotherapy Considerations for Triple-Negative Breast Cancer

S. Tolaney, D. Stover, C. Bell, 2016 .

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.

E. Winer, M. Birrer, Hang Lee, 2013, European journal of cancer.

Targeting HER2 heterogeneity in early-stage breast cancer

S. Tolaney, S. Pernas, 2020, Current opinion in oncology.

Deescalating Treatment in the Adjuvant Setting in Low-Risk HER2-Positive Breast Cancer

R. Barroso-Sousa, S. Tolaney, 2019, Her2-Positive Breast Cancer.

De-escalating treatment in the adjuvant setting in HER2-positive breast cancer.

R. Barroso-Sousa, S. Tolaney, P. Exman, 2018, Future oncology.

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.

E. Winer, X. Liu, Kwok-Kin Wong, 2016, Cancer cell.

Overcoming Therapeutic R esistance in HER 2-Positive Breast Cancers with CDK 4 / 6 Inhibitors Highlights

E. Winer, X. Liu, Kwok-Kin Wong, 2016 .

Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer

E. Winer, H. Burris, M. Maurer, 2014, Breast Cancer Research and Treatment.

Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.

D. Berry, C. Perou, E. Winer, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer.

E. Winer, L. Garraway, O. Cohen, 2020, Cancer discovery.

Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer

G. Shapiro, R. Barroso-Sousa, S. Tolaney, 2016, Breast Care.

Phase I study of sapacitabine and seliciclib in patients with advanced solid tumors.

Jeffrey W. Clark, G. Shapiro, S. Rodig, 2016 .

A phase Ib study of abemaciclib with therapies for metastatic breast cancer.

M. Goetz, M. Beeram, H. Burris, 2015 .

LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer.

P. Wen, K. Flaherty, A. Tolcher, 2014 .

Update on a phase I pharmacologic and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.

A. Oza, G. Shapiro, J. Schellens, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

M. Ellis, E. Winer, C. Hudis, 2015, The New England journal of medicine.

Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to Go

R. Barroso-Sousa, S. Tolaney, 2020, Current Treatment Options in Oncology.

Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer

E. Winer, E. V. Van Allen, L. Macconaill, 2020, Clinical Cancer Research.

Tumor mutational burden as a predictor of immunotherapy response in breast cancer

S. Tolaney, Tess O’Meara, 2021, Oncotarget.

Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler

T. Sørlie, Ö. Sahin, E. Thompson, 2021, Cancers.

Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer

G. Shapiro, D. Proia, N. Spector, 2013, Clinical Cancer Research.

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer

E. Winer, L. Garraway, O. Cohen, 2019, bioRxiv.

Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer

E. Mardis, E. Winer, G. Ha, 2021, JCO precision oncology.

Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial

S. Adams, L. Molinero, J. Diamond, 2019, JAMA oncology.

PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer

Lestat R. Ali, G. Shapiro, S. Goel, 2023, The Journal of experimental medicine.

Acute appendicitis secondary to metastatic carcinoma of the breast: Case report and review of the literature

Lauren L. Ritterhouse, E. Winer, N. Ramaiya, 2015 .

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.

P. Ladenson, J. Califano, D. Sidransky, 2005, The Journal of clinical endocrinology and metabolism.

Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial

A. Siefker-Radtke, S. Tolaney, S. Currie, 2021, Cancer Immunology, Immunotherapy.

PD-L1 Testing in Patients with Breast Cancer: Controversies and Current Practice

S. Tolaney, A. Garrido-Castro, P. Exman, 2019, Current Breast Cancer Reports.

Massively-parallel enrichment of minor alleles for mutational testing via low-depth duplex sequencing

T. Golub, S. Tolaney, S. Reed, 2022, Nature Biomedical Engineering.

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer

A. Giobbie-Hurder, E. Winer, E. V. Van Allen, 2021, Nature Communications.

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1

H. Rugo, H. Wildiers, D. Patt, 2020, Breast Cancer Research and Treatment.

Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?

C. Barrios, R. Barroso-Sousa, S. Tolaney, 2021, NPJ breast cancer.

Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2

R. Jain, Y. Boucher, D. Fukumura, 2018, Science Translational Medicine.

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

E. Winer, O. Cohen, N. Lin, 2019, bioRxiv.

Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors

G. Shapiro, C. Arteaga, D. Cho, 2016, Clinical Cancer Research.

Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study

E. Winer, L. Trippa, S. Schnitt, 2021, NPJ breast cancer.

CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC).

D. Berry, C. Perou, E. Winer, 2019, Journal of Clinical Oncology.

List Website Version Updated April 2018

S. Tolaney, J. Hilton, 2022 .

Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.

Nikhil Wagle, Gad Getz, J Christopher Love, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial

F. Hu, E. Winer, J. Meyerhardt, 2020, Cancer Prevention Research.

328TiP Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09

A. Schneeweiss, S. Loibl, Young-Ae Park, 2021, Annals of Oncology.

Abstract S5-01: Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)

D. Berry, C. Perou, E. Winer, 2013 .

Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction

Barbara L. Smith, E. Winer, J. Brock, 2013, Breast Cancer Research and Treatment.

In Reply to Yilmaz et al.

J. Bellon, S. Tolaney, 2022, International journal of radiation oncology, biology, physics.

Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers

E. Bousoik, S. Tolaney, M. Tolba, 2021, Clinical and Translational Oncology.

Phase 1/2 study of oral rucaparib: Final phase 1 results.

G. Shapiro, P. LoRusso, H. Burris, 2014 .

Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review.

N. Lin, V. Müller, F. Montemurro, 2023, Cancer treatment reviews.

Inhibition of CDK4/6 promotes CD8 T-cell memory formation.

Henry W. Long, Lestat R. Ali, Guocheng Yuan, 2021, Cancer discovery.

CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?

S. Goel, S. Tolaney, 2019, The Lancet. Oncology.

A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer.

P. Wen, K. Flaherty, A. Tolcher, 2013 .

The effects of releasing early results from ongoing clinical trials

L. Trippa, S. Bacallado, B. Alexander, 2021, Nature Communications.

Immunotherapy for the Treatment of Triple-Negative Breast Cancer

S. Tolaney, Lindsay Shaw, 2022, Journal of the advanced practitioner in oncology.

Immunotherapy for early triple negative breast cancer: research agenda for the next decade

H. Rugo, F. André, G. Curigliano, 2022, npj Breast Cancer.

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer

A. Bardia, D. Juric, S. Goel, 2021, NPJ breast cancer.

Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer

N. Lennon, G. Ha, C. Cibulskis, 2021, Genome Medicine.

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

V. Karantza, D. Patt, R. O'Regan, 2021, Clinical Cancer Research.

A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer

N. Lin, C. Anders, P. Kabos, 2020, Clinical Cancer Research.

A Phase II Trial of Cabozantinib in Hormone Receptor‐Positive Breast Cancer with Bone Metastases

J. Baselga, B. Yeap, U. Mahmood, 2020, The oncologist.

A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer.

E. Winer, L. Trippa, J. Bellon, 2020, Clinical breast cancer.

Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial.

E. Winer, L. Trippa, W. Barry, 2019, Clinical breast cancer.

ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.

N. Ibrahim, H. Rugo, C. Anders, 2019, Future oncology.

Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.

Anand A. Dalal, G. Hortobagyi, B. Ramaswamy, 2019, Clinical breast cancer.

Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor

K. Blackwell, H. Burris, S. Isakoff, 2015, Breast Cancer Research and Treatment.

Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer (mTNBC)

P. Sorger, E. Winer, G. Shapiro, 2021 .

Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer

P. Sorger, E. Winer, E. V. Van Allen, 2020, Clinical Cancer Research.

Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial.

E. Winer, L. Trippa, E. V. Van Allen, 2020, JAMA oncology.

Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer

A. Bardia, H. Rugo, J. Diamond, 2019, The New England journal of medicine.

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis

W. Barry, F. Hodi, R. Barroso-Sousa, 2017, JAMA oncology.

A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors

S. Chandarlapaty, G. Shapiro, J. Giltnane, 2020, Clinical Cancer Research.

Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer.

N. Lin, T. Costigan, C. Anders, 2017 .

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer.

M. Ellis, C. Hudis, L. Carey, 2023, The New England journal of medicine.

Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study

M. Galsky, Q. Trinh, R. Haddad, 2022, Annals of Oncology.

Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond

R. Barroso-Sousa, S. Tolaney, 2021, BioDrugs.

Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge.

A. Schneeweiss, E. Perez, M. Piccart, 2021, Cancer treatment reviews.

Mechanisms of trastuzumab resistance in breast cancer.

S. Tolaney, I. Krop, 2009, Anti-Cancer Agents in Medicinal Chemistry.

Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy

A. Giobbie-Hurder, F. Hodi, P. Ott, 2017, Cancer Immunology Research.

Impact of RxPONDER and monarchE on the Surgical Management of the Axilla in Patients With Breast Cancer.

E. Mittendorf, T. King, S. Tolaney, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients

Rakesh K. Jain, Mehra Golshan, Matija Snuderl, 2015, Proceedings of the National Academy of Sciences.

Tumor subtypes and survival in male breast cancer

E. Winer, N. Lin, S. Tolaney, 2021, Breast Cancer Research and Treatment.

Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0

E. Winer, J. Foster, N. Tung, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

R. Gelber, L. Trippa, Minetta C. Liu, 2022, npj Breast Cancer.

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial

E. Winer, R. Gelber, L. Trippa, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nodal Positivity in Early-Stage Triple-Negative Breast Cancer: Implications for Preoperative Immunotherapy

N. Lin, E. Mittendorf, T. King, 2022, Annals of Surgical Oncology.

Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance)

D. Berry, C. Perou, E. Winer, 2016 .

Concordance Between Outside Laboratory Immunohistochemistry Results and Fluorescence In Situ Hybridization ( FISH ) Results from a Central Laboratory

E. Winer, N. Lin, S. Tolaney, 2007 .

A phase I dose-escalation trial of radiation therapy and concurrent cisplatin for stage II and III triple-negative breast cancer.

E. Winer, J. Bellon, A. Taghian, 2021, International journal of radiation oncology, biology, physics.

A phase I study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): safety, tolerability and pharmacokinetic (PK) analysis.

E. Winer, W. Barry, N. Wagle, 2018 .

The evolving understanding of small HER2-positive breast cancers: matching management to outcomes.

S. Tolaney, A. Waks, 2015, Future oncology.

New HER2-Positive Targeting Agents in Clinical Practice

S. Tolaney, 2014, Current Oncology Reports.

MAESTRO affords ‘breadth and depth’ for mutation testing

J. C. Love, T. Golub, S. Tolaney, 2021, bioRxiv.

Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacy

R. Barroso-Sousa, S. Tolaney, 2020, Expert review of anticancer therapy.

The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After Preoperative Chemotherapy

Michael S. Goldberg, C. Perou, E. Winer, 2019, Clinical Cancer Research.

Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses

Peter Schmid, Bo Liu, Rita Nanda, 2017 .

Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC).

S. Adams, L. Molinero, J. Diamond, 2016 .

Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (mBC).

A. Bardia, D. Juric, J. Diamond, 2018 .

Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer.

S. Tyekucheva, S. Schnitt, N. Lin, 2022, JAMA oncology.

Local–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)

M. Ellis, E. Winer, C. Hudis, 2019, Breast Cancer Research and Treatment.

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Lauren L. Ritterhouse, E. Winer, C. Hudis, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract P1-04-05: Multiplexed immunofluorescence staining of intra-tumoral immune cell populations and associations with immunohistochemical, clinical, and pathologic variables in breast cancer

N. Lin, E. Mittendorf, S. Rodig, 2022, Cancer Research.

Phase II study of ruxolitinib , a selective JAK 1 / 2 inhibitor , in patients with metastatic triple-negative breast cancer

E. Winer, K. Polyak, R. Gelman, 2018 .

A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases

E. Winer, L. Trippa, R. Jain, 2019, Breast Cancer Research and Treatment.

Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study

E. Winer, G. Shapiro, A. Awada, 2016, Breast Cancer Research and Treatment.

Abstract P6-15-01: Analysis of renal function in MONARCH 1: A phase 2 study of abemaciclib, a CDK4 & 6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for metastatic breast cancer (MBC)

S. Mukundan, S. Tolaney, J. Cox, 2017 .

A phase 1b study of safety and immune response to PVX-410 vaccine alone and in combination with durvalumab (MEDI4736) in HLA-A2+ patients following adjuvant therapy for stage 2/3 triple negative breast cancer.

W. Barry, S. Adams, N. Tung, 2017 .

Personalized chemotherapy in triple-negative breast cancer: are we ready for prime time?

G. Shapiro, R. Barroso-Sousa, S. Tolaney, 2019, Stem cell investigation.

Abstract GS1-07: Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results

A. Bardia, J. Diamond, J. O’Shaughnessy, 2018 .

A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1).

V. Karantza, D. Patt, R. O'Regan, 2020 .

Adjuvant Abemaciclib Combined with Endocrine Therapy for High Risk Early Breast Cancer: Safety and Patient-Reported Outcomes From the monarchE Study.

H. Rugo, J. O’Shaughnessy, M. Gumus, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer

Sara R. Selitsky, C. Fan, C. Perou, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC).

E. Winer, L. Trippa, D. Dillon, 2019, Journal of Clinical Oncology.

Abstract GS4-01: Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane

P. Fasching, Sung-Bae Kim, M. Piccart, 2021 .

Abstract P1-19-01: A phase 2 study of abemaciclib in patients with leptomeningeal metastases secondary to HR+, HER2- breast cancer

S. Tolaney, Yanyun Chen, S. Sahebjam, 2019, Poster Session Abstracts.

LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)

A. Bardia, F. Marmé, F. Dalenc, 2022, Annals of Oncology.

Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study.

L. Carey, A. Bardia, H. Rugo, 2022, Journal of Clinical Oncology.

A phase Ib study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+ breast cancer (MBC).

E. Winer, B. Overmoyer, E. Mittendorf, 2020 .

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study

M. Goetz, M. Beeram, H. Burris, 2022, Frontiers in Oncology.

Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced brea

E. Winer, D. Lake, C. Hudis, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan

G. MacBeath, G. Shapiro, Sunil Sharma, 2017, Investigational New Drugs.

249PAnalysis of overall survival by tumor response in MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, in women with HR+/HER2- metastatic breast cancer (MBC) after chemotherapy for advanced disease

J. Baselga, H. Rugo, H. Wildiers, 2017 .

Abstract CT044: MONARCH 1: Final overall survival analysis of a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease

J. Baselga, H. Rugo, H. Wildiers, 2017 .

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

A. Bardia, H. Rugo, R. Leon-Ferre, 2022, Breast Cancer Research and Treatment.

Randomized Phase II Trial of Exercise, Metformin, or Both on Metabolic Biomarkers in Colorectal and Breast Cancer Survivors

F. Hu, E. Winer, J. Meyerhardt, 2019, JNCI cancer spectrum.

Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial.

L. Trippa, A. Bardia, N. Tung, 2022, Journal of Clinical Oncology.

Randomized trial of a clinic-based weight loss intervention in cancer survivors

Justin C. Brown, A. Partridge, J. Ligibel, 2016, Journal of Cancer Survivorship.

Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).

A. Bardia, H. Rugo, S. Loibl, 2021 .

Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

S. Mallal, S. Loi, R. Salgado, 2020, Clinical Cancer Research.

Abstract PD13-07: Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer

L. Carey, A. Bardia, H. Rugo, 2021 .

A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer

E. Winer, J. Bellon, J. Brock, 2014, Cancer Medicine.

Abstract GS3-02: Invasive disease-free survival and gene expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2-targeting with lapatinib added to chemotherapy plus trastuzumab

D. Berry, C. Perou, E. Winer, 2018 .

Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.

M. Ellis, E. Winer, C. Hudis, 2016, JAMA oncology.

The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced pretreated HER2-low breast cancer.

S. Tolaney, P. Tarantino, I. Schlam, 2023, Expert review of anticancer therapy.

How I treat HER2-low advanced breast cancer

S. Tolaney, P. Tarantino, I. Schlam, 2023, Breast.

Abstract OT2-07-07: ATR inhibitor M6620 (formerly VX-970) with cisplatin in metastatic triple-negative breast cancer: Preliminary results from a phase 1 dose expansion cohort (NCT02157792)

G. Shapiro, G. Conboy, J. Pollard, 2018 .

HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications.

J. Bellon, G. Curigliano, M. Regan, 2022, European journal of cancer.

Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry

E. Winer, N. Lin, M. Hassett, 2021, Breast Cancer Research and Treatment.

92MO Neoadjuvant nivolumab (NIVO) + palbociclib (PALBO) + anastrozole (ANA) for estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) primary breast cancer (BC): CheckMate 7A8

G. Jerusalem, S. Tolaney, F. Ades, 2022, Annals of Oncology.

Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib.

E. Mittendorf, S. Tolaney, P. Tarantino, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC).

M. Ellis, E. Winer, C. Hudis, 2017 .

Abstract GS3-06: Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

L. Carey, A. Bardia, H. Rugo, 2021 .

Abstract PS11-09: Impact ofUGT1A1status on the safety profile of sacituzumab govitecan in the phase 3 ASCENT study in patients with metastatic triple-negative breast cancer

M. Piccart, L. Carey, A. Bardia, 2021 .

Targeting the androgen receptor (AR) in women with AR+ ER-/PR- metastatic breast cancer (MBC).

C. Hudis, Minetta C. Liu, L. Carey, 2012 .

Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors

F. Peale, G. Shapiro, P. LoRusso, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer

S. Tolaney, P. Tarantino, S. Sammons, 2023, Cancers.

Abstract GS2-10: Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC)

E. Winer, S. Reddy, B. Overmoyer, 2022, Cancer Research.

214MO Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study

A. Bardia, F. Marmé, M. Motwani, 2022, Annals of Oncology.

Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons.

G. Curigliano, S. Tolaney, P. Tarantino, 2022, Cancer discovery.

1MO Prognostic and biologic significance of HER2-low expression in early breast cancer

S. Tyekucheva, S. Schnitt, N. Lin, 2022, Annals of Oncology.

NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.

J. Larkin, N. Ibrahim, S. Gettinger, 2018 .

Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis

Brian L. Shaw, A. Giobbie-Hurder, R. Sullivan, 2020, Nature Network Boston.

Abstract S3-06: Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer

D. Berry, E. Mardis, C. Perou, 2015 .

LBA18 Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): A randomized, open-label, phase II trial

H. Denys, S. Tolaney, J. Nadal, 2022, Annals of Oncology.

Database Selection and Heterogeneity-More Details, More Credibility-Reply.

W. Barry, R. Barroso-Sousa, S. Tolaney, 2018, JAMA oncology.

Evidence to date: talazoparib in the treatment of breast cancer

R. Barroso-Sousa, S. Tolaney, P. Exman, 2019, OncoTargets and therapy.

Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan

N. Lin, C. Lascola, C. Anders, 2023, npj Breast Cancer.

Exploring the impact of exercise and mind–body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgery

A. Giobbie-Hurder, E. Winer, A. McTiernan, 2021, Supportive Care in Cancer.

Nodal positivity and systemic therapy among patients with clinical T1–T2N0 human epidermal growth factor receptor‐positive breast cancer: Results from two international cohorts

E. Mittendorf, T. King, A. Prat, 2023, Cancer.

A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer

E. Winer, N. Tung, E. Mittendorf, 2022, NPJ breast cancer.

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.

P. Neven, Chiun-Sheng Huang, H. Rugo, 2022, The Lancet. Oncology.

Local therapy outcomes and toxicity from the (anonymized for review) trial: A phase II randomized trial of adjuvant trastuzumab emtansine vs. paclitaxel in combination with trastuzumab in women with stage I HER2-positive breast cancer

E. Winer, J. Bellon, H. Burstein, 2022, International Journal of Radiation Oncology, Biology, Physics.

A phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense (dd) doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC).

E. Winer, R. Jain, Y. Boucher, 2012 .

Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP).

E. Winer, N. Lin, M. Hughes, 2022, Journal of Clinical Oncology.

Follow-up care of patients with breast cancer.

E. Winer, S. Tolaney, 2007, Breast.

Correction: Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.

Hong Wang, P. Neven, A. Llombart-Cussac, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

AZD8186 study 1: phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer an

S. Barry, G. Shapiro, J. Bono, 2016 .

CDK4/6 inhibitors in advanced hormone receptor-positive breast cancer

R. Barroso-Sousa, S. Tolaney, 2017 .

Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT).

E. Winer, R. Berger, R. Kurzrock, 2012 .

Abstract CT050: Expansion cohort of Phase I study of oral sapacitabine and oral seliciclib in patients with metastatic breast cancer andBRCA1/2mutations

David R. Liu, E. Winer, G. Shapiro, 2019, Clinical Trials.

Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer - Authors' reply.

N. Harbeck, J. O’Shaughnessy, S. Tolaney, 2023, The Lancet. Oncology.

Abstract P2-11-06: Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer

S. Adams, L. Molinero, J. Diamond, 2016 .

Phase II study of pembrolizumab in leptomeningeal carcinomatosis.

A. Giobbie-Hurder, S. Carter, S. Prakadan, 2018 .

A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancer.

E. Winer, U. Matulonis, C. Whalen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease.

J. Baselga, H. Rugo, H. Wildiers, 2016 .

The effects of a clinic‐based weight loss program on health‐related quality of life and weight maintenance in cancer survivors: A randomized controlled trial

A. Giobbie-Hurder, Justin C. Brown, A. Partridge, 2021, Psycho-oncology.

Management of Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

S. Tolaney, S. Pernas, 2021, JCO oncology practice.

Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results

A. Giobbie-Hurder, P. Wen, D. Cahill, 2023, Nature Medicine.

The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer

H. Burstein, S. Tolaney, A. Grinshpun, 2023, npj Breast Cancer.

Abstract CT108: A phase 1b study of abemaciclib in combination with pembrolizumab for patients (pts) with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (mBC) (NCT02779751): Preliminary results

H. Rugo, H. Wildiers, P. Kabos, 2020 .

Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies

J. Garber, N. Lin, G. Curigliano, 2023, The oncologist.

ESMO Expert Consensus Statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer.

E. Provenzano, L. Carey, A. Vincent-Salomon, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of Hormone Receptors With Clinical Outcomes in Patients With ERBB2-Low Breast Cancer-Reply.

S. Tolaney, P. Tarantino, N. Tayob, 2022, JAMA oncology.

The Dawn of the Antibody-Drug Conjugates Era: How T-DM1 Reinvented the Future of Chemotherapy for Solid Tumors.

S. Tolaney, P. Tarantino, 2022, Cancer Research.

Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.

C. Perou, L. Carey, A. Wolff, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Elacestrant: Who are optimal candidates for the first oral SERD?

S. Tolaney, M. Lipsyc-Sharf, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Significance of PIK3CA and ESR1 Mutations in circulating tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib Plus Fulvestrant.

P. Neven, Hong Wang, G. Sledge, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Reversion and non-reversion mechanisms of resistance (MoR) to PARP inhibitor (PARPi) or platinum chemotherapy (chemotx) in patients (pts) with BRCA1/2-mutant metastatic breast cancer (MBC).

E. Winer, O. Cohen, G. Shapiro, 2019, Journal of Clinical Oncology.

Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab.

C. Perou, J. Parker, E. Mittendorf, 2023, JAMA oncology.

Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.

C. Perou, J. Parker, N. Tung, 2023, JAMA oncology.

M. Piccart, L. Carey, A. Bardia, 2021, Annals of Oncology.

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer

A. Bardia, D. Juric, S. Goel, 2021, npj Breast Cancer.

Abstract PD2-09: The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC)

E. Winer, L. Garraway, Pingping Mao, 2020 .

Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer

N. Lin, M. Hassett, S. Tolaney, 2022, Cancer.

Efficacy of neoadjuvant chemotherapy (NAC) in male breast cancer (MaBC) compared with female breast cancer (FBC): A National Cancer Database (NCDB) study.

E. Winer, M. Hassett, S. Tolaney, 2020 .

AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

H. Iwata, N. Ternès, M. Campone, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract CT045: Ribociclib + letrozole for first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers

G. Hortobagyi, F. André, M. Campone, 2017 .

Nimbus: A phase II study of nivolumab plus ipilimumab in metastatic hypermutated HER2-negative breast cancer.

E. Winer, L. Trippa, H. Rugo, 2019, Journal of Clinical Oncology.

Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison

A. Bardia, H. Rugo, F. Cardoso, 2023, Therapeutic advances in medical oncology.

The association of early toxicity and outcomes for patients treated with abemaciclib.

G. Sledge, H. Rugo, M. Goetz, 2018 .

Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP

J. Foster, W. Woodward, L. Pusztai, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor–Positive Breast Cancer: Implications for Guidance and Reimbursement

N. Lin, H. Burstein, J. Brock, 2023, JCO oncology practice.

Abstract 4458: Clinical significance ofPIK3CAandESR1mutations in ctDNA and FFPE samples from the MONARCH 2 study of abemaciclib plus fulvestrant

P. Neven, G. Sledge, A. Llombart-Cussac, 2019, Clinical Research (Excluding Clinical Trials).

Abstract PD1-03: Multivariate analysis of subtype and gene expression signatures predictive of pathologic complete response (pCR) in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)

D. Berry, C. Fan, C. Perou, 2017 .

Aiming for the Cure in ERBB2-Positive Metastatic Breast Cancer-Should We Go "All In"?-Reply.

S. Tolaney, P. Tarantino, H. Parsons, 2022, JAMA oncology.

Abstract OT2-01-07: A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)

H. Wildiers, L. Gianni, P. Kabos, 2017 .

Tailoring the Treatment of Early-stage HER2-positive Breast Cancer: One Size Does Not Fit All

S. Tolaney, P. Tarantino, A. Waks, 2023, Oncology & Haematology.

Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial.

N. Ibrahim, H. Rugo, C. Anders, 2022, JAMA oncology.

Optimizing the safety of antibody–drug conjugates for patients with solid tumours

S. Tolaney, P. Tarantino, B. Ricciuti, 2023, Nature Reviews Clinical Oncology.

Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis

Brian L. Shaw, A. Giobbie-Hurder, S. Carter, 2020, Nature Medicine.

Prognosis and trends in chemotherapy use for patients with stage IA triple-negative breast cancer (TNBC): A population-based study.

N. Lin, S. Tolaney, P. Tarantino, 2023, Journal of Clinical Oncology.

Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities

R. Barroso-Sousa, S. Tolaney, S. Sammons, 2023, Cancers.

Estimating mortality in women with triple-negative breast cancer: the ‘ESTIMATE triple-negative’ tool

N. Lin, M. Hassett, S. Tolaney, 2023, European Journal of Cancer.

Integration of Physician and Nursing Professional Efforts to Deliver Supportive Scalp Cooling Care to Oncology Patients at Risk for Alopecia

S. Isakoff, S. Tolaney, M. Lustberg, 2020, Oncology and Therapy.

Cardiology patient page. Breast cancer chemotherapy and your heart.

J. Moslehi, S. Tolaney, K. Montazeri, 2014, Circulation.

MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)

S. Goel, A. Wardley, S. Im, 2019, Annals of Oncology.

Abstract P1-12-04: Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in patients (pts) with HER2+ breast cancer brain metastases

E. Winer, William H. Barry, S. Tolaney, 2017 .

Abstract P3-09-15: A phase 1b study of PVX-410 (PVX) vaccine plus durvalumab (DUR) as adjuvant therapy in HLA-A2+ early stage triple negative breast cancer (eTNBC) to assess safety and immune response

L. Trippa, W. Barry, S. Adams, 2020 .

Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go?

G. Curigliano, N. Harbeck, S. Tolaney, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer

N. Tung, E. Mittendorf, T. King, 2022, npj Breast Cancer.

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Shaughnessy, O. J., L. Carey, 2022 .

Structural and functional vascular dysfunction within brain metastases is linked to pembrolizumab inefficacy

Praveer Singh, A. Giobbie-Hurder, Jayashree Kalpathy-Cramer, 2023, bioRxiv.

RF28 | PSUN185 The effects of diabetes and glycemic control on cancer outcomes in individuals with metastatic breast cancer

N. Lin, M. Hughes, S. Tolaney, 2022, The Journal of clinical endocrinology and metabolism.

Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study

M. Galsky, J. Riess, M. Robson, 2023, medRxiv.

Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8.

A. Prat, S. Tolaney, P. Nikolinakos, 2023, Breast.

Abstract GS3-06: GS3-06 Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer

A. DeMichele, H. Burstein, M. Regan, 2023, Cancer Research.

Abstract P3-14-03: A phase 1b study of the CDK4/6 inhibitor ribociclib in combination with the PD-1 inhibitor spartalizumab in patients with hormone receptor-positive metastatic breast cancer (HR+ MBC) and metastatic ovarian cancer (MOC)

E. Winer, L. Trippa, A. Bardia, 2020 .

A phase II study of pembrolizumab in combination with palliative radiotherapy (RT) for hormone receptor-positive (HR+) metastatic breast cancer (MBC).

E. Winer, L. Trippa, D. Dillon, 2019, Journal of Clinical Oncology.

Occurrence and significance of morphologic changes in patients with metastatic triple negative breast cancer treated with Cabozantinib.

A. Shinagare, N. Ramaiya, S. Tolaney, 2018, Clinical imaging.

HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance

S. Tolaney, S. Pernas, 2019, Therapeutic advances in medical oncology.

Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.

S. Tolaney, P. Tarantino, S. Morganti, 2023, Critical reviews in oncology/hematology.

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.

M. Ellis, C. Hudis, L. Carey, 2023, The Lancet. Oncology.

Adjuvant abemaciclib for high-risk early breast cancer (EBC): Factors increasing the rate of treatment discontinuations in monarchE.

N. Harbeck, Miguel Martín, S. Tolaney, 2022, Journal of Clinical Oncology.

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer.

M. Ellis, E. Winer, C. Hudis, 2015, The New England journal of medicine.

Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.

E. Winer, S. Edge, C. Shapiro, 2010, Journal of the National Cancer Institute.

Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents

C. Criscitiello, G. Curigliano, S. Gandini, 2023, The oncologist.

Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

D. Berry, E. Mardis, C. Fan, 2018, Clinical Cancer Research.

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

A. Bardia, H. Rugo, F. Marmé, 2023, The Lancet.

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

M. Piccart, L. Carey, A. Bardia, 2021, New England Journal of Medicine.

Abstract GS1-11: Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC): Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients (Pts) With HR+/HER2– Metastatic Breast Cancer (mBC)

A. Bardia, H. Rugo, F. Marmé, 2023, Cancer Research.

A Phase II Trial of Cabozantinib in Hormone Receptor‐Positive Breast Cancer with Bone Metastases

J. Baselga, B. Yeap, U. Mahmood, 2020, The oncologist.

Liquid biopsy epigenomic profiling for cancer subtyping

K. Ligon, T. Choueiri, M. Freedman, 2023, Nature Medicine.

Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial

P. Neven, G. Sledge, H. Rugo, 2021, Breast cancer research : BCR.

Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2− advanced breast cancer: a review

S. Tolaney, R. Freedman, 2018, Breast Cancer Research and Treatment.

CDK4/6 inhibitors in advanced hormone receptor-positive breast cancer

R. Barroso-Sousa, S. Tolaney, 2017 .

Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer

G. Shapiro, R. Barroso-Sousa, S. Tolaney, 2016, Breast Care.

Endometrial Cancer Risk Among Germline BRCA1/2 Pathogenic Variant Carriers: Review of Our Current Understanding and Next Steps

C. Feltmate, S. Tolaney, F. Lynce, 2023, JCO precision oncology.

Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure

S. Tolaney, P. Tarantino, D. Trapani, 2023, ESMO open.

Advancing equitable and personalized cancer care: Novel applications and priorities of artificial intelligence for fairness and inclusivity in the patient care workflow.

C. Criscitiello, S. Tolaney, E. Dee, 2023, European journal of cancer.

Abstract 2638: Sacituzumab Govitecan, combination with PARP inhibitor, Talazoparib, in metastatic triple-negative breast cancer (TNBC): Translational investigation

A. Niemierko, A. Bardia, D. Juric, 2022, Cancer Research.

Clinical efficacy of CDK4/6 inhibitor plus endocrine therapy in HR-positive/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA-3 trials

J. Plichta, S. Tolaney, Salil Koner, 2024, EBioMedicine.

PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer

A. DeMichele, H. Burstein, K. Miller, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interstitial lung disease and CDK4/6 inhibitors in the treatment of breast cancer

S. Tolaney, I. Schlam, Antonio Giordano, 2023, Expert opinion on drug safety.

Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2− advanced breast cancer

H. Rugo, D. Yardley, K. Jhaveri, 2023, Therapeutic advances in medical oncology.

Response-guided neoadjuvant sacituzumab govitecan for localized triple negative breast cancer: results from the NeoSTAR trial.

L. Trippa, L. Ellisen, A. Comander, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC).

A. Bardia, H. Rugo, F. Marmé, 2023, Journal of Clinical Oncology.